Benexate (BEX) is an anti-ulcer agent used in the treatment of acid-related disorders. It is unique in its inability to form salts that are both non-bitter and soluble.[1][2]

Benexate
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
administration
Oral
ATC code
  • none
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
  • Phenylmethyl 2-[4-[(diaminomethylideneamino)methyl]cyclohexanecarbonyl]oxybenzoate
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC23H27N3O4
Molar mass409.486 g·mol−1
3D model (JSmol)
  • O=C(OCc1ccccc1)c3ccccc3OC(=O)C2CCC(C/N=C(\N)N)CC2
  • InChI=1S/C23H27N3O4/c24-23(25)26-14-16-10-12-18(13-11-16)21(27)30-20-9-5-4-8-19(20)22(28)29-15-17-6-2-1-3-7-17/h1-9,16,18H,10-15H2,(H4,24,25,26) checkY
  • Key:IAXUQWSLRKIRFR-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Medical uses

edit

Benexate is approved from treatment of gastric ulcer in Japan.[3]

Mechanism of action

edit

The mechanism of action of benexate involves promotion of prostaglandin synthesis, protein secretion, and blood flow stimulation in the gastrointestinal tract.[4]

See also

edit

References

edit
  1. ^ Hori Y, Odaguchi K, Jyoyama H, Yasui K, Mizui T (1996). "Differential effect of benexate hydrochloride betadex on prostaglandin levels in stomach and inflammatory sites in rats". Japanese Journal of Pharmacology. 72 (2): 183–190. doi:10.1254/jjp.72.183. PMID 8912919.
  2. ^ Muranushi N, Yoshida M, Kinoshita H, Hirose F, Fukuda T, Doteuchi M, Yamada H (1998). "Studies of benexate CD: effect of inclusion compound formation on the antiulcer activity of benexate, the effective ingredient of benexate CD". Folia Pharmacologica Japonica (91): 377–383.
  3. ^ "Benexate". Inxight Drugs. National Center for Advancing Translational Sciences.
  4. ^ Lee JM, Lim J, Kim Y, Kim YJ, Choi HS, Kim ES, Keum B, Seo YS, Jeen YT, Lee HS, Um SH, Kim CD, Ryu HS, Sul D, Hong J, Chun HJ (2016). "Benexate hydrochloride betadex modulates nitric oxide synthesis and cytokine expression in gastric ulcers". Experimental and Therapeutic Medicine. 12 (2): 573–580. doi:10.3892/etm.2016.3384. PMC 4950842. PMID 27446246.

Further reading

edit